MX2022010157A - Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. - Google Patents

Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.

Info

Publication number
MX2022010157A
MX2022010157A MX2022010157A MX2022010157A MX2022010157A MX 2022010157 A MX2022010157 A MX 2022010157A MX 2022010157 A MX2022010157 A MX 2022010157A MX 2022010157 A MX2022010157 A MX 2022010157A MX 2022010157 A MX2022010157 A MX 2022010157A
Authority
MX
Mexico
Prior art keywords
cell receptors
mutation
restricted
hla class
tcrs
Prior art date
Application number
MX2022010157A
Other languages
English (en)
Spanish (es)
Inventor
Steven A Rosenberg
Noam Levin
Biman C Paria
Rami Yoseph
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2022010157A publication Critical patent/MX2022010157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
MX2022010157A 2020-02-26 2021-02-26 Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. MX2022010157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062981856P 2020-02-26 2020-02-26
PCT/US2021/019775 WO2021173902A1 (en) 2020-02-26 2021-02-26 Hla class ii-restricted t cell receptors against ras with g12v mutation

Publications (1)

Publication Number Publication Date
MX2022010157A true MX2022010157A (es) 2022-10-18

Family

ID=74885105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010157A MX2022010157A (es) 2020-02-26 2021-02-26 Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.

Country Status (12)

Country Link
US (1) US20230159614A1 (enExample)
EP (1) EP4110804A1 (enExample)
JP (1) JP7742354B2 (enExample)
KR (1) KR20220143939A (enExample)
CN (1) CN115244075A (enExample)
AU (1) AU2021225872A1 (enExample)
BR (1) BR112022016661A2 (enExample)
CA (1) CA3169086A1 (enExample)
GB (1) GB2610069B (enExample)
MX (1) MX2022010157A (enExample)
TW (1) TWI900533B (enExample)
WO (1) WO2021173902A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
KR20250037592A (ko) 2017-09-20 2025-03-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
CR20200287A (es) * 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
WO2019129892A1 (en) * 2017-12-29 2019-07-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
GB201804724D0 (en) * 2018-03-23 2018-05-09 Univ Oslo Hf Method of diagnosing cceliac disease
WO2019231326A1 (en) * 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
WO2022183167A1 (en) * 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Also Published As

Publication number Publication date
CN115244075A (zh) 2022-10-25
EP4110804A1 (en) 2023-01-04
KR20220143939A (ko) 2022-10-25
AU2021225872A1 (en) 2022-09-15
GB2610069A (en) 2023-02-22
BR112022016661A2 (pt) 2022-10-11
GB2610069B (en) 2025-04-16
US20230159614A1 (en) 2023-05-25
TWI900533B (zh) 2025-10-11
JP7742354B2 (ja) 2025-09-19
WO2021173902A1 (en) 2021-09-02
GB202212195D0 (en) 2022-10-05
CA3169086A1 (en) 2021-09-02
TW202140537A (zh) 2021-11-01
JP2023527613A (ja) 2023-06-30

Similar Documents

Publication Publication Date Title
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
MX2022009654A (es) Receptor de células t restringido por hla de la clase i contra ras con mutación g12d.
MX2022010157A (es) Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.
MX2024005678A (es) Receptores de celulas t que reconocen p53 mutado.
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
CY1125601T1 (el) Υποδοχεις anti-kras-g12d κυτταρων τ
ES2317378T3 (es) Peptidos asociados a tumor unidos a moleculas mhc.
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
WO2019036043A2 (en) METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
US20220241331A1 (en) Identification of recurrent mutated neopeptides
CN106589105B (zh) Hla-a2限制性ecm1特异性的ctl表位肽及其应用
WO2022098936A1 (en) Selecting neoantigens for personalized cancer vaccine
WO2022015694A8 (en) Hla class ii–restricted drb t cell receptors against ras with g12d mutation
Yao et al. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer
WO2024206274A3 (en) T cell receptors targeting y220c or r175h mutation in p53
WO2021262829A3 (en) Hla class i-restricted t cell receptors against cd20
CN116287158A (zh) 一种新抗原鉴定和疗效预测方法
WO2022051449A3 (en) T cell receptors recognizing r273c or y220c mutations in p53
AU2024311891A1 (en) Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
US20240082304A1 (en) Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
Schmidt et al. Serological and immunochemical studies of H‐2 allospecificities on K36, a syngeneic tumour of AKR
KR102182555B1 (ko) T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼
EP3447066A1 (en) New ccl2 peptides for use in cancer therapy